|
|
FDA Reports Risk of Delayed Onset Inflammation Near Dermal Filler Treatment Sites
Today, the U.S. Food and Drug Administration (FDA) is updating its page on Dermal Fillers (Soft Tissue Fillers) to reflect information from reports of delayed onset inflammation such as swelling or redness that can develop near the dermal filler injection site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation is responsive to treatment or resolves on its own.
The FDA encourages consumers and patients to discuss all treatment options, including dermal filler procedures, with their health care provider to understand the benefits and risks associated with the use of these medical devices.
Questions?
If you have questions, contact the Division of Industry and Consumer Education.
|
|
|
|
